Classys Reports Nine-Month 2026 Revenue of KRW 275.7 Billion, Up 13% Year over Year; Prepares to Accelerate Growth in 2027 on China Entry, U.S. and Europe Expansion, New Product Launches and Direct-Operations Integration

• Nine-month revenue of KRW 275.7 billion and operating profit of KRW 108.1 billion; revenue up 13% year over year
• China market entry and broader product lineups in the U.S. and Europe strengthen the foundation for medium- to long-term growth
• New devices and cartridges in Korea, together with the stabilization of the LATAM and Japan direct-operations subsidiaries, are expected to speed up profitability improvement

SEOUL, South Korea, Nov. 13, 2026 — Classys Inc. (KOSDAQ: 214150), a global medical aesthetics company, announced on November 12 (KST) its results for the third quarter of 2026. On a consolidated basis, nine-month revenue was KRW 275.7 billion and operating profit was KRW 108.1 billion. Revenue increased 13% year over year, while operating profit decreased 9.4%. For the third quarter alone, revenue was KRW 83.0 billion, roughly flat year over year; operating profit was KRW 27.0 billion, for an operating margin of 32.5%.

The third quarter was a period in which near-term pressure on results came together: lower sales in Korea as the Company's core products entered a generational transition, and the shift of LATAM and Japan to direct operations. In LATAM, the Company incurred initial costs to normalize operations at its direct-operations subsidiary, and distribution margin recognized during the sell-through of inventory held before the acquisition of Medsystems (now Classys Brasil) was limited. In Japan, upfront investment related to the transition to direct operations also affected profitability.

The Company views these as temporary integration costs arising from the restructuring of its global business and a product launch cycle. It expects this pressure to ease gradually, and plans to accelerate its recovery and global growth through the stabilization of its direct-operations structure and business expansion in large markets such as China. The Company expects its growing cumulative global unit sales, which have surpassed 50,000 units as of October 2026, along with its accumulated brand, technology and product strengths and its cash-generating capacity, to support this acceleration.

China
Ahead of its first product approval in China, the Company expects growth momentum in this large market to build. China is becoming a market where companies must obtain formal regulatory approval as approval barriers rise, and demand is expanding mainly for newly approved devices. Classys expects approval of Volnewmer, its globally successful device, in December, and is in discussions with prospective large local partners on distribution agreements. The Company also expects approval of Ultraformer (known as Shurink in Korea) in the first half of 2027 and of its new product Viclara in the second half. By broadening the range of products it can sell in China, the Company plans to respond to a wider range of procedure demand in stages and pursue faster revenue growth and improved profitability.

U.S. and Europe
The U.S., Europe and other regions are large markets with relatively low penetration and ample room for further growth. In the U.S., the Company is operating mainly with Everesse (marketed as Volnewmer in Korea) and its new product Quadessy. It plans to use the customer base built with Everesse to introduce Viclara, Reepot and Ultraformer in sequence, to expand its product portfolio and accelerate revenue growth. In Europe, building on the business models confirmed in Spain and Turkey, the Company plans to actively expand the market with a broader lineup than its competitors, including Ultraformer and Volnewmer, as well as Quadessy, Viclara and Veloce.

Korea
In Korea, the Company has begun full-scale marketing for its new four-wavelength laser device Fortra, featuring a famous model, and expects Fortra to grow alongside Shurink Universe, Volnewmer and Quadessy. In the first half of 2027, the Company plans to introduce a new procedure protocol and a new Volnewmer tip, as part of a strategy to grow device and consumables revenue together. It also plans to launch a new HIFU product with higher output than the existing Shurink Universe, to strengthen its market leadership.

Direct-operations -  LATM and Japan
At the LATAM direct-operations subsidiary, the Company expects a transition to a normal margin structure as the sell-through of pre-acquisition inventory is completed. It is also making strategic investments in organizational reinforcement, brand repositioning and B2C marketing, and plans to expand cross-selling of Volnewmer, Quadessy and laser products to Ultraformer customers. At the Japan direct-operations subsidiary, the Company plans to expand its customer base centered on large clinic chains and to accelerate sales of Volnewmer and Quadessy.

"In the third quarter we faced a weak domestic market and profitability pressure at our overseas direct-operations subsidiaries, but we continue to secure new growth opportunities on the strength of more than 50,000 cumulative units sold, including the largest cumulative HIFU unit sales in the global industry," said CEO Jun-oh Yoon. "We have been bringing in new global top-level executives, including Vice President and Chief Commercial Officer Jung-hee Bae and Chief Technology Officer Dr. Taek-Soo Kim, fully reorganized the company around markets and customers, and completed the operating framework for product innovation and global growth and expansion. Through China market entry, a broader lineup in the U.S. and Europe, and innovative new product launches, we aim to accelerate revenue growth, and we will focus on improving profitability by normalizing operations at our direct-operations subsidiaries.

SOURCE Classys Inc.